Click for best price
CAR TCell Therapy for Multiple Myeloma Market Size, Share 2024
| Market size in 2023 |
US$ 154.7 million
|
Forecast Market size by 2030 |
US$ 1014 million
|
| Growth Rate |
CAGR of 31.5% |
Number of Pages |
73 Pages |
This research report provides a comprehensive analysis of the CAR T-Cell Therapy for Multiple Myeloma market, focusing on the current trends, market dynamics, and future prospects. The report explores the global CAR T-Cell Therapy for Multiple Myeloma market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of CAR T-Cell Therapy for Multiple Myeloma, challenges faced by the industry, and potential opportunities for market players.
The global CAR T-Cell Therapy for Multiple Myeloma market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The CAR T-Cell Therapy for Multiple Myeloma market presents opportunities for various stakeholders, including Multiple Myeloma, Refractory or Relapsed Multiple Myeloma. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in CAR T-Cell Therapy for Multiple Myeloma market. Additionally, the growing consumer demand present avenues for market expansion.
The global CAR T-Cell Therapy for Multiple Myeloma market was valued at US$ 154.7 million in 2023 and is projected to reach US$ 1014 million by 2030, at a CAGR of 31.5% during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The research report on the CAR T-Cell Therapy for Multiple Myeloma market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the CAR T-Cell Therapy for Multiple Myeloma market.
Market Overview: The report provides a comprehensive overview of the CAR T-Cell Therapy for Multiple Myeloma market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Monotherapy, Combination Therapy), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the CAR T-Cell Therapy for Multiple Myeloma market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the CAR T-Cell Therapy for Multiple Myeloma market's trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the CAR T-Cell Therapy for Multiple Myeloma market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the CAR T-Cell Therapy for Multiple Myeloma market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the CAR T-Cell Therapy for Multiple Myeloma market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the CAR T-Cell Therapy for Multiple Myeloma market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for CAR T-Cell Therapy for Multiple Myeloma, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the CAR T-Cell Therapy for Multiple Myeloma market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
CAR T-Cell Therapy for Multiple Myeloma market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Monotherapy
Combination Therapy
Market segment by Application
Multiple Myeloma
Refractory or Relapsed Multiple Myeloma
Global CAR T-Cell Therapy for Multiple Myeloma Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Juno Therapeutics
Kite Pharma
Novartis
Collectis
Outline of Major Chapters:
Chapter 1: Introduces the definition of CAR T-Cell Therapy for Multiple Myeloma, market overview.
Chapter 2: Global CAR T-Cell Therapy for Multiple Myeloma market size in revenue.
Chapter 3: Detailed analysis of CAR T-Cell Therapy for Multiple Myeloma company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of CAR T-Cell Therapy for Multiple Myeloma in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
CAR T-Cell Therapy for Multiple Myeloma Market, Global Outlook and Forecast 2024-2030 |
| Market size in 2023 |
US$ 154.7 million
|
| Forecast Market size by 2030 |
US$ 1014 million
|
| Growth Rate |
CAGR of 31.5% |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2023 |
| Forecast Year |
2031 |
| Number of Pages |
73 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 CAR T-Cell Therapy for Multiple Myeloma Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global CAR T-Cell Therapy for Multiple Myeloma Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global CAR T-Cell Therapy for Multiple Myeloma Overall Market Size
2.1 Global CAR T-Cell Therapy for Multiple Myeloma Market Size: 2023 VS 2030
2.2 Global CAR T-Cell Therapy for Multiple Myeloma Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top CAR T-Cell Therapy for Multiple Myeloma Players in Global Market
3.2 Top Global CAR T-Cell Therapy for Multiple Myeloma Companies Ranked by Revenue
3.3 Global CAR T-Cell Therapy for Multiple Myeloma Revenue by Companies
3.4 Top 3 and Top 5 CAR T-Cell Therapy for Multiple Myeloma Companies in Global Market, by Revenue in 2023
3.5 Global Companies CAR T-Cell Therapy for Multiple Myeloma Product Type
3.6 Tier 1, Tier 2 and Tier 3 CAR T-Cell Therapy for Multiple Myeloma Players in Global Market
3.6.1 List of Global Tier 1 CAR T-Cell Therapy for Multiple Myeloma Companies
3.6.2 List of Global Tier 2 and Tier 3 CAR T-Cell Therapy for Multiple Myeloma Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global CAR T-Cell Therapy for Multiple Myeloma Market Size Markets, 2023 & 2030
4.1.2 Monotherapy
4.1.3 Combination Therapy
4.2 By Type - Global CAR T-Cell Therapy for Multiple Myeloma Revenue & Forecasts
4.2.1 By Type - Global CAR T-Cell Therapy for Multiple Myeloma Revenue, 2019-2024
4.2.2 By Type - Global CAR T-Cell Therapy for Multiple Myeloma Revenue, 2025-2030
4.2.3 By Type - Global CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global CAR T-Cell Therapy for Multiple Myeloma Market Size, 2023 & 2030
5.1.2 Multiple Myeloma
5.1.3 Refractory or Relapsed Multiple Myeloma
5.2 By Application - Global CAR T-Cell Therapy for Multiple Myeloma Revenue & Forecasts
5.2.1 By Application - Global CAR T-Cell Therapy for Multiple Myeloma Revenue, 2019-2024
5.2.2 By Application - Global CAR T-Cell Therapy for Multiple Myeloma Revenue, 2025-2030
5.2.3 By Application - Global CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global CAR T-Cell Therapy for Multiple Myeloma Market Size, 2023 & 2030
6.2 By Region - Global CAR T-Cell Therapy for Multiple Myeloma Revenue & Forecasts
6.2.1 By Region - Global CAR T-Cell Therapy for Multiple Myeloma Revenue, 2019-2024
6.2.2 By Region - Global CAR T-Cell Therapy for Multiple Myeloma Revenue, 2025-2030
6.2.3 By Region - Global CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America CAR T-Cell Therapy for Multiple Myeloma Revenue, 2019-2030
6.3.2 US CAR T-Cell Therapy for Multiple Myeloma Market Size, 2019-2030
6.3.3 Canada CAR T-Cell Therapy for Multiple Myeloma Market Size, 2019-2030
6.3.4 Mexico CAR T-Cell Therapy for Multiple Myeloma Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe CAR T-Cell Therapy for Multiple Myeloma Revenue, 2019-2030
6.4.2 Germany CAR T-Cell Therapy for Multiple Myeloma Market Size, 2019-2030
6.4.3 France CAR T-Cell Therapy for Multiple Myeloma Market Size, 2019-2030
6.4.4 U.K. CAR T-Cell Therapy for Multiple Myeloma Market Size, 2019-2030
6.4.5 Italy CAR T-Cell Therapy for Multiple Myeloma Market Size, 2019-2030
6.4.6 Russia CAR T-Cell Therapy for Multiple Myeloma Market Size, 2019-2030
6.4.7 Nordic Countries CAR T-Cell Therapy for Multiple Myeloma Market Size, 2019-2030
6.4.8 Benelux CAR T-Cell Therapy for Multiple Myeloma Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia CAR T-Cell Therapy for Multiple Myeloma Revenue, 2019-2030
6.5.2 China CAR T-Cell Therapy for Multiple Myeloma Market Size, 2019-2030
6.5.3 Japan CAR T-Cell Therapy for Multiple Myeloma Market Size, 2019-2030
6.5.4 South Korea CAR T-Cell Therapy for Multiple Myeloma Market Size, 2019-2030
6.5.5 Southeast Asia CAR T-Cell Therapy for Multiple Myeloma Market Size, 2019-2030
6.5.6 India CAR T-Cell Therapy for Multiple Myeloma Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America CAR T-Cell Therapy for Multiple Myeloma Revenue, 2019-2030
6.6.2 Brazil CAR T-Cell Therapy for Multiple Myeloma Market Size, 2019-2030
6.6.3 Argentina CAR T-Cell Therapy for Multiple Myeloma Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa CAR T-Cell Therapy for Multiple Myeloma Revenue, 2019-2030
6.7.2 Turkey CAR T-Cell Therapy for Multiple Myeloma Market Size, 2019-2030
6.7.3 Israel CAR T-Cell Therapy for Multiple Myeloma Market Size, 2019-2030
6.7.4 Saudi Arabia CAR T-Cell Therapy for Multiple Myeloma Market Size, 2019-2030
6.7.5 UAE CAR T-Cell Therapy for Multiple Myeloma Market Size, 2019-2030
7 CAR T-Cell Therapy for Multiple Myeloma Companies Profiles
7.1 Juno Therapeutics
7.1.1 Juno Therapeutics Company Summary
7.1.2 Juno Therapeutics Business Overview
7.1.3 Juno Therapeutics CAR T-Cell Therapy for Multiple Myeloma Major Product Offerings
7.1.4 Juno Therapeutics CAR T-Cell Therapy for Multiple Myeloma Revenue in Global Market (2019-2024)
7.1.5 Juno Therapeutics Key News & Latest Developments
7.2 Kite Pharma
7.2.1 Kite Pharma Company Summary
7.2.2 Kite Pharma Business Overview
7.2.3 Kite Pharma CAR T-Cell Therapy for Multiple Myeloma Major Product Offerings
7.2.4 Kite Pharma CAR T-Cell Therapy for Multiple Myeloma Revenue in Global Market (2019-2024)
7.2.5 Kite Pharma Key News & Latest Developments
7.3 Novartis
7.3.1 Novartis Company Summary
7.3.2 Novartis Business Overview
7.3.3 Novartis CAR T-Cell Therapy for Multiple Myeloma Major Product Offerings
7.3.4 Novartis CAR T-Cell Therapy for Multiple Myeloma Revenue in Global Market (2019-2024)
7.3.5 Novartis Key News & Latest Developments
7.4 Collectis
7.4.1 Collectis Company Summary
7.4.2 Collectis Business Overview
7.4.3 Collectis CAR T-Cell Therapy for Multiple Myeloma Major Product Offerings
7.4.4 Collectis CAR T-Cell Therapy for Multiple Myeloma Revenue in Global Market (2019-2024)
7.4.5 Collectis Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. CAR T-Cell Therapy for Multiple Myeloma Market Opportunities & Trends in Global Market
Table 2. CAR T-Cell Therapy for Multiple Myeloma Market Drivers in Global Market
Table 3. CAR T-Cell Therapy for Multiple Myeloma Market Restraints in Global Market
Table 4. Key Players of CAR T-Cell Therapy for Multiple Myeloma in Global Market
Table 5. Top CAR T-Cell Therapy for Multiple Myeloma Players in Global Market, Ranking by Revenue (2023)
Table 6. Global CAR T-Cell Therapy for Multiple Myeloma Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global CAR T-Cell Therapy for Multiple Myeloma Revenue Share by Companies, 2019-2024
Table 8. Global Companies CAR T-Cell Therapy for Multiple Myeloma Product Type
Table 9. List of Global Tier 1 CAR T-Cell Therapy for Multiple Myeloma Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 CAR T-Cell Therapy for Multiple Myeloma Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - CAR T-Cell Therapy for Multiple Myeloma Revenue in Global (US$, Mn), 2019-2024
Table 13. By Type - CAR T-Cell Therapy for Multiple Myeloma Revenue in Global (US$, Mn), 2025-2030
Table 14. By Application ? Global CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2023 & 2030
Table 15. By Application - CAR T-Cell Therapy for Multiple Myeloma Revenue in Global (US$, Mn), 2019-2024
Table 16. By Application - CAR T-Cell Therapy for Multiple Myeloma Revenue in Global (US$, Mn), 2025-2030
Table 17. By Region ? Global CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global CAR T-Cell Therapy for Multiple Myeloma Revenue (US$, Mn), 2019-2024
Table 19. By Region - Global CAR T-Cell Therapy for Multiple Myeloma Revenue (US$, Mn), 2025-2030
Table 20. By Country - North America CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2025-2030
Table 30. Juno Therapeutics Company Summary
Table 31. Juno Therapeutics CAR T-Cell Therapy for Multiple Myeloma Product Offerings
Table 32. Juno Therapeutics CAR T-Cell Therapy for Multiple Myeloma Revenue (US$, Mn) & (2019-2024)
Table 33. Juno Therapeutics Key News & Latest Developments
Table 34. Kite Pharma Company Summary
Table 35. Kite Pharma CAR T-Cell Therapy for Multiple Myeloma Product Offerings
Table 36. Kite Pharma CAR T-Cell Therapy for Multiple Myeloma Revenue (US$, Mn) & (2019-2024)
Table 37. Kite Pharma Key News & Latest Developments
Table 38. Novartis Company Summary
Table 39. Novartis CAR T-Cell Therapy for Multiple Myeloma Product Offerings
Table 40. Novartis CAR T-Cell Therapy for Multiple Myeloma Revenue (US$, Mn) & (2019-2024)
Table 41. Novartis Key News & Latest Developments
Table 42. Collectis Company Summary
Table 43. Collectis CAR T-Cell Therapy for Multiple Myeloma Product Offerings
Table 44. Collectis CAR T-Cell Therapy for Multiple Myeloma Revenue (US$, Mn) & (2019-2024)
Table 45. Collectis Key News & Latest Developments
List of Figures
Figure 1. CAR T-Cell Therapy for Multiple Myeloma Segment by Type in 2023
Figure 2. CAR T-Cell Therapy for Multiple Myeloma Segment by Application in 2023
Figure 3. Global CAR T-Cell Therapy for Multiple Myeloma Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global CAR T-Cell Therapy for Multiple Myeloma Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global CAR T-Cell Therapy for Multiple Myeloma Revenue, 2019-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by CAR T-Cell Therapy for Multiple Myeloma Revenue in 2023
Figure 8. By Type - Global CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share, 2019-2030
Figure 9. By Application - Global CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share, 2019-2030
Figure 10. By Type - Global CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2023 & 2030
Figure 11. By Type - Global CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share, 2019-2030
Figure 12. By Application - Global CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2023 & 2030
Figure 13. By Application - Global CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share, 2019-2030
Figure 14. By Region - Global CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share, 2019-2030
Figure 15. By Country - North America CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share, 2019-2030
Figure 16. US CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2019-2030
Figure 17. Canada CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2019-2030
Figure 18. Mexico CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2019-2030
Figure 19. By Country - Europe CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share, 2019-2030
Figure 20. Germany CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2019-2030
Figure 21. France CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2019-2030
Figure 22. U.K. CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2019-2030
Figure 23. Italy CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2019-2030
Figure 24. Russia CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2019-2030
Figure 25. Nordic Countries CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2019-2030
Figure 26. Benelux CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2019-2030
Figure 27. By Region - Asia CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share, 2019-2030
Figure 28. China CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2019-2030
Figure 29. Japan CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2019-2030
Figure 30. South Korea CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2019-2030
Figure 31. Southeast Asia CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2019-2030
Figure 32. India CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2019-2030
Figure 33. By Country - South America CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share, 2019-2030
Figure 34. Brazil CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2019-2030
Figure 35. Argentina CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2019-2030
Figure 36. By Country - Middle East & Africa CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share, 2019-2030
Figure 37. Turkey CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2019-2030
Figure 38. Israel CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2019-2030
Figure 39. Saudi Arabia CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2019-2030
Figure 40. UAE CAR T-Cell Therapy for Multiple Myeloma Revenue, (US$, Mn), 2019-2030
Figure 41. Juno Therapeutics CAR T-Cell Therapy for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. Kite Pharma CAR T-Cell Therapy for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. Novartis CAR T-Cell Therapy for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. Collectis CAR T-Cell Therapy for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
